Thyrotrophin receptor signaling dependence of Braf-induced thyroid tumor initiation in mice. - Wikidata - awgldk - TriplyDB

Thyrotrophin receptor signaling dependence of Braf-induced thyroid tumor initiation in mice.

Thyrotrophin receptor signaling dependence of Braf-induced thyroid tumor initiation in mice.

http://www.wikidata.org/entity/Q34533804

about

Proto-oncogene PBF/PTTG1IP regulates thyroid cell growth and represses radioiodide treatment Time to re-consider the meaning of BRAF V600E mutation in papillary thyroid carcinoma Personalized therapy in patients with anaplastic thyroid cancer: targeting genetic and epigenetic alterations Integrated genomic characterization of papillary thyroid carcinoma STAT3 negatively regulates thyroid tumorigenesis Oncogenic BRAF disrupts thyroid morphogenesis and function via twist expression.Follicular thyroid cancers demonstrate dual activation of PKA and mTOR as modeled by thyroid-specific deletion of Prkar1a and Pten in mice.VEGFR2 but not VEGFR3 governs integrity and remodeling of thyroid angiofollicular unit in normal state and during goitrogenesis.Progression of BRAF-induced thyroid cancer is associated with epithelial-mesenchymal transition requiring concomitant MAP kinase and TGFβ signaling.Stemness is Derived from Thyroid Cancer Cells.Anaplastic Thyroid Carcinoma: Current Treatments and Potential New Therapeutic Options with Emphasis on TfR1/CD71.Molecular pathogenesis and mechanisms of thyroid cancer Identification of sumoylation sites in CCDC6, the first identified RET partner gene in papillary thyroid carcinoma, uncovers a mode of regulating CCDC6 function on CREB1 transcriptional activity.Synergistic signaling of KRAS and thyroid hormone receptor β mutants promotes undifferentiated thyroid cancer through MYC up-regulation.Genetic and pharmacological targeting of CSF-1/CSF-1R inhibits tumor-associated macrophages and impairs BRAF-induced thyroid cancer progression.Mutationally activated BRAF(V600E) elicits papillary thyroid cancer in the adult mouse TSH signaling overcomes B-RafV600E-induced senescence in papillary thyroid carcinogenesis through regulation of DUSP6.Identification of BRAF mutations in eruptive melanocytic nevi: new insights into melanomagenesis?Hypoxia-inducible factor in thyroid carcinoma Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation.The Usefulness of Preoperative Thyroid-Stimulating Hormone for Predicting Differentiated Thyroid Microcarcinoma.BRAFV600E-Associated Gene Expression Profile: Early Changes in the Transcriptome, Based on a Transgenic Mouse Model of Papillary Thyroid Carcinoma.Orthotopic mouse models for the preclinical and translational study of targeted therapies against metastatic human thyroid carcinoma with BRAF(V600E) or wild-type BRAF miR-200c/Bmi1 axis and epithelial-mesenchymal transition contribute to acquired resistance to BRAF inhibitor treatment.Mouse models of thyroid cancer: A 2015 update.Update in TSH receptor agonists and antagonists Metastasis-associated MCL1 and P16 copy number alterations dictate resistance to vemurafenib in a BRAFV600E patient-derived papillary thyroid carcinoma preclinical model.Clinical outcomes and molecular profile of differentiated thyroid cancers with radioiodine-avid distant metastases.Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas.Fibroblast-Mediated Collagen Remodeling Within the Tumor Microenvironment Facilitates Progression of Thyroid Cancers Driven by BrafV600E and Pten Loss.miRNA-106a directly targeting RARB associates with the expression of Na(+)/I(-) symporter in thyroid cancer by regulating MAPK signaling pathway.Thrombospondin-1 Silencing Down-Regulates Integrin Expression Levels in Human Anaplastic Thyroid Cancer Cells with BRAF(V600E): New Insights in the Host Tissue Adaptation and Homeostasis of Tumor Microenvironment Obatoclax kills anaplastic thyroid cancer cells by inducing lysosome neutralization and necrosis Metformin blocks progression of obesity-activated thyroid cancer in a mouse model.Prognosis of differentiated thyroid cancer in relation to serum thyrotropin and thyroglobulin antibody status at time of diagnosis.Immune Suppression Mediated by Myeloid and Lymphoid Derived Immune Cells in the Tumor Microenvironment Facilitates Progression of Thyroid Cancers Driven by HrasG12V and Pten Loss.Thyrotropin signaling confers more aggressive features with higher genomic instability on BRAF(V600E)-induced thyroid tumors in a mouse model Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma.Multiple Hürthle cell adenomas in a patient with thyroid hormone resistance The next generation of orthotopic thyroid cancer models: immunocompetent orthotopic mouse models of BRAF V600E-positive papillary and anaplastic thyroid carcinoma

P2860

Q24635291-A619BF46-3011-4D49-AA83-56CFBBAB38CF Q26853261-E9003C5B-EAA9-4A44-B506-530D0CE7053C Q27027491-D21AF035-832B-4385-AA39-8AE55D4124FF Q28251986-579F9542-CEA8-4797-8068-4C9F43AB09EF Q28505424-CC2E9B52-688E-4A88-8070-4D8A73EF1F3D Q33558907-C51F74CF-51FF-4CFE-8999-D2415D240A86 Q33569087-8BC44A10-3BC0-44C9-8086-D40933FAB520 Q33748993-DCC45177-0D1E-4294-8562-A0A3C08C1C09 Q33839230-744A9AAF-011D-4E8B-98D5-D1B349B7100E Q33901058-87E34BD0-A204-4C30-89A8-64C855368403 Q33914771-13BB8C7D-3A95-4915-BE30-46457632CB15 Q34329018-0E945FAE-81A2-420C-B18C-D9D594495CF3 Q34474368-94A39DD2-B1BD-4E1F-9347-D37B07DC0579 Q34528284-ACC029D8-3D6C-4C7E-B44E-3EA9245BB688 Q34571096-99F96E19-4D16-4594-A917-173C3C5E1638 Q35022217-39E63724-F6D1-49DF-9A70-3F789B2AEF40 Q35022501-AC167117-683F-4A83-988D-2350E134FAD4 Q35059440-B03EB1EF-AC2E-458C-854D-105DCD66F166 Q35099457-B839945C-97DF-4EE9-9729-678782B0F1D1 Q35578577-26F8C978-7798-4DB1-86C5-407DBE8A9330 Q35849441-6361A350-C9D1-4115-9264-D054767BE992 Q35857363-7B9269A2-3FE0-409B-B4B6-A1A3C29A39C0 Q35914464-C341837B-9D30-4A76-8782-38A7B1C81F74 Q36135379-C23A39BF-0D35-4504-9E61-AF4D8BB713B2 Q36405539-B36C05F6-E0CA-4A20-A2E3-8D41B3DEB753 Q36442422-207D3160-8AB5-4F4F-9210-BBD5FE9B1BFC Q36618887-ECAFE5D7-B47D-4E35-B55A-22E85EA17F2A Q36817229-ACE4DBCE-E5BB-4307-B1C2-EC26099B39C2 Q36836677-239A8859-338F-4C6B-935A-82899905599C Q36917756-8567849C-93A2-4EB5-85CC-A3B3AB2D4277 Q37035505-3A9143C9-1C8B-45B4-ADA5-E0ADBFE14D97 Q37353828-8CC730AD-710B-4310-90FF-1A5D807E1CB6 Q37376300-7792D172-68AE-4C66-9A35-0E7A4D9EE931 Q37376404-557F0D07-743D-4EBC-B006-79EC4784B6DB Q37460181-64EF544E-77EF-4C69-B4D1-9AF1226189AF Q37486166-325C148F-2B80-4D48-B033-895D1955FB83 Q37630088-FEE049F4-2684-49D5-9C26-57BC2C660207 Q37660341-9F4221AB-94AE-451C-9146-2D87EB7B1DE1 Q37662277-239F6DB6-C254-4CA9-A18B-6C3E4DF64F31 Q37712700-2A4F9FF5-B6DA-4A62-80B7-9AE3B05EDA47

P2860

Thyrotrophin receptor signaling dependence of Braf-induced thyroid tumor initiation in mice.

http://www.wikidata.org/entity/Q34533804

description

2011 nî lūn-bûn

@nan

2011 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Thyrotrophin receptor signalin ...... roid tumor initiation in mice.

@ast

Thyrotrophin receptor signalin ...... roid tumor initiation in mice.

@en

Thyrotrophin receptor signalin ...... roid tumor initiation in mice.

@nl

type

label

Thyrotrophin receptor signalin ...... roid tumor initiation in mice.

@ast

Thyrotrophin receptor signalin ...... roid tumor initiation in mice.

@en

Thyrotrophin receptor signalin ...... roid tumor initiation in mice.

@nl

prefLabel

Thyrotrophin receptor signalin ...... roid tumor initiation in mice.

@ast

Thyrotrophin receptor signalin ...... roid tumor initiation in mice.

@en

Thyrotrophin receptor signalin ...... roid tumor initiation in mice.

@nl

P1433

Q34533804-2170017F-7C66-489D-A5BC-FC81A1774683

P1476

Q34533804-151BC8D6-57B6-47F3-9E53-3BFB73113B73

P2093

Q34533804-099C9421-63E9-4EA9-BE87-EA6ADB38361D

Q34533804-11351915-494F-4143-8321-C3205CAE5403

Q34533804-1AEF8E5C-2022-49FF-BDBD-ACC9AD2849BB

Q34533804-2DA43263-6B1D-430A-8E32-170D9A8F273C

Q34533804-3DC56107-13EC-4D22-8372-A5590216B14C

Q34533804-56F34EB4-0224-43D2-B89C-F21D61A94784

Q34533804-8B59E982-BF94-4241-87BC-6BF915CDE7B3

Q34533804-AEC8262B-AE60-4981-A2CD-77B72D4564F3

Q34533804-C6EEF70C-DFAC-4375-910F-61FACB131F34

Q34533804-D7D1A280-EFFA-4079-ACFF-ABA06DFAD8E1

P2860

Q34533804-069DD7EA-E8A9-485F-9C34-3C495DBAB9BC

Q34533804-077B115E-18AA-4CDC-95BB-31E088C13B7B

Q34533804-0B98EC7B-287D-4611-8FA7-326370930B2C

Q34533804-1AEBB99D-6A97-421C-83B7-3E01D55F03D9

Q34533804-1C50480A-2234-4079-A494-4618E8ABB9C2

Q34533804-20637DC3-EE8B-4C89-98C1-6C02923157F7

Q34533804-20C124EF-BFDA-4E19-90C1-0B280B386FEE

Q34533804-2233AEEF-275B-4CFB-9B4B-D5EF54EDF823

Q34533804-2279D4D2-9DED-4A78-999F-D6F1E6760537

Q34533804-287C211A-4FD5-4B63-8AF0-8CEF06B1CADB

P304

Q34533804-B3AF896E-32BC-4045-A917-3AEF1E9A36BF

P31

Q34533804-B96164B1-25A3-4DE9-A0F3-616E223D1DF7

P356

Q34533804-27FC3328-8CE1-4390-A5AE-DA25711062C2

P407

Q34533804-2119B9B9-F7A8-4BC7-9EDA-FB32DCCC7264

P433

Q34533804-E70BAA3C-FA29-4A71-9911-9E83B995ED77

P478

Q34533804-042F37DC-6130-4542-877D-84BCA977324D

P50

Q34533804-42306021-CD03-4697-8AB5-73935B688933

Q34533804-5A626F18-F1F8-4F6E-9EEF-CBB8AAB6F541

Q34533804-9C6FACA9-B396-4E75-A241-A1DBC2230F36

Q34533804-D25C508E-3173-49F8-B944-E02031CC275C

P577

Q34533804-52C29E36-CC9A-4B4D-BE4C-EA27BD1F4382

P5875

Q34533804-93B28DC2-C62B-4AE3-8CFD-42293563C9E7

P698

Q34533804-C9F595A5-515F-4CEF-86CC-0F34161E62B7

P932

Q34533804-D42D80EA-9C3D-40AF-A01F-BEEC3E7BDFA6

P356

PNAS.1015557108

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Thyrotrophin receptor signalin ...... roid tumor initiation in mice.

@en

P2093

Aime T Franco

http://www.w3.org/2001/XMLSchema#string

Emma Lundsmith

http://www.w3.org/2001/XMLSchema#string

James A Fagin

http://www.w3.org/2001/XMLSchema#string

Min Chen

http://www.w3.org/2001/XMLSchema#string

Neal Rosen

http://www.w3.org/2001/XMLSchema#string

Roberta Malaguarnera

http://www.w3.org/2001/XMLSchema#string

Ronald Ghossein

http://www.w3.org/2001/XMLSchema#string

Samuel Refetoff

http://www.w3.org/2001/XMLSchema#string

Shioko Kimura

http://www.w3.org/2001/XMLSchema#string

Terry F Davies

http://www.w3.org/2001/XMLSchema#string

P2860

Multiple ras downstream pathways mediate functional repression of the homeobox gene product TTF-1

Mutations of the BRAF gene in human cancer

BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study

Two G protein oncogenes in human endocrine tumors

Higher serum thyroid stimulating hormone level in thyroid nodule patients is associated with greater risks of differentiated thyroid cancer and advanced tumor stage.

High frequency of BRAF mutations in nevi.

Role of the thyroid-stimulating hormone receptor signaling in development and differentiation of the thyroid gland.

Defining thyrotropin-dependent and -independent steps of thyroid hormone synthesis by using thyrotropin receptor-null mice.

Regulation of thyroid cell proliferation by TSH and other factors: a critical evaluation of in vitro models.

BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas.

P304

1615-1620

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.1015557108

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

108

http://www.w3.org/2001/XMLSchema#string

P50

Lee S. Weinstein

Jeffrey A Knauf

Catrin Pritchard

P577

2011-01-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49741904

http://www.w3.org/2001/XMLSchema#string

P698

21220306

http://www.w3.org/2001/XMLSchema#string

P932

3029699

http://www.w3.org/2001/XMLSchema#string